JPRN-jRCT2031230113尚未招募2 期
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
Bateman J. Randall0 个研究点目标入组 10 人开始时间: 2023年6月7日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 80age old（—）
- 性别
- All
入选标准
- •Between 18-80 years of age
- •- Individuals who know they have an Alzheimer's disease-causing mutation.
- •- Are within -10 to + 10 years of the predicted or actual age of cognitive symptom onset.
- •- Cognitively normal or with mild cognitive impairment or mild dementia, Clinical Dementia Rating (CDR) of 0-1 (inclusive)
- •- Fluency in DIAN-TU trial approved language and evidence of adequate premorbid intellectual functioning
- •- Able to undergo Magnetic Resonance Imaging (MRI), Lumbar Puncture (LP), Positron Emission Tomography (PET), and complete all study related testing and evaluations.
- •- People of childbearing potential (POCBP), if partner is not sterilized, participant must agree to use highly effective contraceptive measures (hormonal contraception, intra-uterine device, sexual abstinence, vasectomized partner).
- •- Adequate visual and auditory abilities to perform all aspects of the cognitive and functional assessments.
- •- Has a Study Partner who in the investigator's judgment is able to provide accurate information as to the subject's cognitive and functional abilities, who agrees to provide information at the study visits which require informant input for scale completion.
排除标准
- •- Significant neurologic disease (other than AD) or psychiatric disease that may currently or during the course of the study affect cognition or participant's ability to complete the study.
- •- At high risk for suicide, e.g., significant suicidal ideation or attempt within last 12 months. Current stable mild depression or current use of antidepressant medications is not exclusionary.
- •- History or presence of brain MRI scans indicative of any other significant abnormality
- •- Substance or alcohol use disorder currently or within the past 1 year
- •- Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, or foreign metal objects in the eyes, skin or body which would preclude MRI scan.
- •- History or presence of clinically significant cardiovascular disease, hepatic/renal disorders, infectious disease or immune disorder, or metabolic/endocrine disorders
- •- Anticoagulants except low dose (<= 325 mg) aspirin.
- •- Have been exposed to a monoclonal antibody targeting beta amyloid peptide within the past six months.
- •- History of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer or carcinoma in situ with no significant progression over the past 2 years.
- •- Positive urine or serum pregnancy test or plans or desires to become pregnant during the course of the trial.
- •- Subjects unable to complete all study related testing, including implanted metal that cannot be removed for MRI scanning, required anticoagulation and pregnancy.
研究者
相似试验
招募中
1 期
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Early Onset Alzheimer's Disease Caused by a Genetic MutatioDominantly Inherited Alzheimer Disease (DIAD)CTIS2024-515198-91-00Washington University School Of Medicine540
进行中（未招募）
不适用
A Phase IIIB Multi-center, Randomized, Double-Blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate Naive Early Erosive RA Subjects Treated with Abatacept plus Methotrexate Compared with MethotrexateProtocol Version 1.0 dated 06-May-2005, andProtocol Amendments 3 & 4 - Site Specific dated 28-Dec-2005.EUCTR2005-000784-26-ATBristol Myers Squibb International Corporation750
进行中（未招募）
不适用
A Phase IIIB Multi-center, Randomized, Double-Blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate Naive Early Erosive RA Subjects Treated with Abatacept plus Methotrexate Compared with MethotrexateProtocol Version 1.0 dated 06-May-2005 + Amendment 1 dated 16-May-2005.EUCTR2005-000784-26-IEBristol Myers Squibb International Corporation750
进行中（未招募）
1 期
A Phase IIIB Multi-center, Randomized, Double-Blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate Naive Early Erosive RA Subjects Treated with Abatacept plus Methotrexate Compared with Methotrexate.Rheumatoid Arthritis, NosEUCTR2005-000784-26-ESBristol Myers Squibb International Corporation750
进行中（未招募）
1 期
A Phase IIIB Multi-center, Randomized, Double-Blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate Naive Early Erosive RA Subjects Treated with Abatacept plus Methotrexate Compared with Methotrexate Revised Protocol 04, incorporating Protocol Amendments 05, 06, 08, 09 (V1.0 dated 18-Nov-2008) and Administrative Letter 02. Pharmacogenetics Amendment 1 dated 16-May-2005. Protocol Amendments 3 & 4 - Site Specific - dated 28-Dec-2005.Rheumatoid Arthritis, NosEUCTR2005-000784-26-GBBristol Myers Squibb International Corporation750